Nelfinavir

Nelfinavir is an oral antiretroviral agent. Nelfinavir is a protease inhibitor, belongs to the group that includes indinavir , ritonavir and saquinavir. Nelfinavir is used in conjunction with nucleoside reverse transcriptase inhibitors , for the treatment of HIV infection. Nelfinavir is a competitive inhibitor of HIV protease, an enzyme involved in the replication of HIV. Protease is responsible for cleaving precursor molecules (immuture budding particles) to produce the final structural proteins of a mature virion core and to activate reverse transcriptase for a new round of infection. Thus, protease is necessary for the production of mature virions. Protease inhibition renders the virus noninfectious. Because they inhibit the HIV replication cycle after translation and before assembly, HIV protease inhibitors are active in acutely and chronically infected cells, as well as in cells (e.g., monocytes and macrophages) not normally affected by dideoxynucleoside reverse transcriptase inhibitors.


Adult Dose
Dose: 750 mg
Single Dose: 750 (750)
Frequency: 8 hourly
Route: PO
Instructions:
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin. . The Molecular Weight of Nelfinavir is 663.90.
Contraindications
Nelfinavir
Effects
The severe or irreversible adverse effects of Nelfinavir, which give rise to further complications include Renal impairment, Paresthesia, Myalgia, Lipodystrophy.The symptomatic adverse reactions produced by Nelfinavir are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Headache, Fatigue, Diarrhea, Pruritus, Taste disturbance, Asthenia, Nausea and vomiting, dizziness, Rash.
Indications
Nelfinavir is primarily indicated in conditions like HIV infection.
Interactions
Nelfinavir is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAbacavirPhenytoin reduces plasma concentration of abacavir. Afatinibma increase the level of afatinibuse alternative or reduce doseAmiodarone (HCl)Nelfinavir may decrease the metabolism, via CYP isoenzymes, of Amiodarone. ADVICE:The concomitant use of Nelfinavir and amiodarone should be avoided.MajorAmobarbitalAmobarbital possibly reduces plasma concentration of Nelfinavir.MajorAstemizoleCisaprideClarithromycinDidanosineDihydroergotamine (Mesylate)Ergotamine (Tartrate)ErlotinibThis CYP3A4 inhibitor increases levels/toxicity of erlotinibErythromycinEstrogens ConjugatedFlecainide (Acetate)HalazepamMidazolamOmeprazoleProgesteronePropafenone (HCl)QuinidineRifabutinRifampicinSaquinavirSunitinibMay increases sunitinib concentrations.TerfenadineTheophyllineTriazolamVORICONAZOLENelfinavir may decrease the serum concentration of voriconazole likely by increasing its metabolism. Consider alternate therapy or adjust doses Zolpidem (Tartrate) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, and Cardiac / Hypertensive Patients.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab, Oral Powder Store in a well closed container, at room temperature.
Warnings
Caution is required in diabetic patient, patients with hemophilia who may experienced increased bleeding. It should be used with caution and possible dose reduction is needed in hepatic impairment. Adequate hydration is recommended to avoid any risk of nephrolithiasis. Monotoring is required in case of renal impairment.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.